Surgical Treatment and Prognosis Analysis of Primary Carcinoma of Gallbladder
Clinical Medicine Research
Volume 6, Issue 3, May 2017, Pages: 111-115
Received: May 4, 2017; Published: May 4, 2017
Views 2002      Downloads 115
Authors
Guotao Fang, The Second Ward Department of Oncology, Affiliated Hospital of Hebei University, Baoding, P. R. China
Qi Zhang, Department of Clinical Medicine, Medical College of HeBei University, Baoding, P. R. China
Article Tools
Follow on us
Abstract
To discuss the effects of different treatment methods on the prognosis of primary carcinoma of gallbladder (PCG) patients. The clinical statistics of 99 cases of PCG patients were retrospectively analyzed, and the prognosis multivariate analysis was performed. Results: 52% of the patients suffered from PCG and gallstones simultaneously, and 82.8% (82/99) of the patients were diagnosed as PCG before surgeries. 86 cases of patients were subjected to routine exploratory surgeryies, and the radical resection rate was 33.72% (29/86). The overall 5-year survival rate was 6.28%, and the 1-year, 3-year and 5-year survival rates of the radical resection group were 78.43%, 48.49% and 23.77%, respectively. The results were significantly different from those of the palliative surgery group, the exploratory laparotomy group and the non-surgical group. The multivariate analysis of Cox model reveals that surgical method was significantly correlated with the invasion depth of tumor and the prognosis of gallbladder carcinoma. The treatment efficacy of PCG might be improved by increasing the early diagnosis rate and performing radical resection which are accompanied by radiotherapy and chemotherapy.
Keywords
Gallbladder Tumor, Surgery, Prognostic Factor
To cite this article
Guotao Fang, Qi Zhang, Surgical Treatment and Prognosis Analysis of Primary Carcinoma of Gallbladder, Clinical Medicine Research. Vol. 6, No. 3, 2017, pp. 111-115. doi: 10.11648/j.cmr.20170603.19
References
[1]
Cho SY, Han SS, et al. T-category reflects the histopathologic characteristics of gallbladder carcinoma [J]. Eur J Surg Oncol, 2012, 38 (6): 537-42.
[2]
Ghosh M, Bhattacharyya NK, Ghoshsengupta S. Carcinoid tumour of gall bladder--a case report [J]. J Indian Med Assoc, 2011, 109 (3): 198-9.
[3]
Kim K, Chie EK,et al. Postoperative chemoradiotherapy for gallbladder carcinoma [J].Strahlenther Onkol, 2012, 188 (5): 388-92.
[4]
Pais-Costa SR, Farah JF, et al. Gallbladder adenocarcinoma: evaluation of the prognostic factors in 100 resectable cases in Brazil [J]. Arq Bras Cir Dig, 2012, 25 (1)13-9.
[5]
Kim KH, Kim TN. Etiology, clinical features, and endoscopic management of hemobilia: a retrospective analysis of 37 cases [J]. Korean J Gastroenterol, 2012, 59 (4) 296-302.
[6]
Yao X, Zhou L, Han S, Chen Y. High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder carcinoma [J]. J Int Med Res, 2011, 39 (4): 1253-64.
[7]
Wakai T, Ajioka Y,et al. Morphological features of early gallbladder carcinoma [J]. Hepatogastroenterology, 2012, 59 (116): 1013-7.
[8]
Giang TH, Ngoc TT, Hassell LA. Carcinoma involving the gallbladder: a retrospective review of 23 cases - pitfalls in diagnosis of gallbladder carcinoma [J]. Diagn Pathol, 2012, 27 (7): 10-11.
[9]
Hijioka S, Ikari T, et al. US - IDUS - EUS for diagnosis of biliary tract neoplasms [J]. Nihon Rinsho, 2006, 64 (1): 393-7.
[10]
Konstantinidis IT, Bajpai S,et al. Gallbladder lesions identified on ultrasound. Lessons from the last 10 years [J]. J Gastrointest Surg, 2012, 16 (3): 549-53.
[11]
Kumar R, Sharma P, et al. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma [J]. Clin Nucl Med, 2012, 37 (5): 431-5.
[12]
Todoroki T, Takahashi H et al. Outcomes of aggressive treatment of stage IV gallbladder carcinoma and predictors of survival [J]. Hepatogastroenterology, 1999, 46 (28): 2114-21.
[13]
Choi SB, Han HJ, et al. Fourteen year surgical experience of gallbladder carcinoma: validity of curative resection affecting survival [J]. Hepatogastroenterology, 2012, 59 (113): 36-41.
[14]
Wang SJ, Lemieux A, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resectedgallbladder carcinoma [J]. J Clin Oncol, 2011, 29 (35): 4627-32.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186